The serum concentration of Domperidone can be increased when it is combined with Lovastatin. The metabolism of Domperidone can be decreased when combined with Caffeine. Sertraline may increase the QTc-prolonging activities of Domperidone. Pazopanib may increase the QTc-prolonging activities of Domperidone. The metabolism of Domperidone can be increased when combined with Fosphenytoin. Mirabegron may increase the QTc-prolonging activities of Domperidone. The metabolism of Domperidone can be decreased when combined with Clobazam. The risk or severity of adverse effects can be increased when Moclobemide is combined with Domperidone. Lithium may increase the QTc-prolonging activities of Domperidone. The metabolism of Domperidone can be decreased when combined with Cimetidine. The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Domperidone. The metabolism of Domperidone can be decreased when combined with Fluoxetine. The serum concentration of Domperidone can be decreased when it is combined with Tocilizumab. Arformoterol may increase the QTc-prolonging activities of Domperidone. The serum concentration of Domperidone can be increased when it is combined with Isradipine. The serum concentration of Domperidone can be increased when it is combined with Osimertinib. The risk or severity of adverse effects can be increased when Minaprine is combined with Domperidone. The serum concentration of Domperidone can be increased when it is combined with Atomoxetine. The risk or severity of adverse effects can be increased when Nialamide is combined with Domperidone. Maprotiline may increase the QTc-prolonging activities of Domperidone. Mirtazapine may increase the QTc-prolonging activities of Domperidone. Pasireotide may increase the QTc-prolonging activities of Domperidone. The serum concentration of Domperidone can be increased when it is combined with Sildenafil. The risk or severity of QTc prolongation can be increased when Domperidone is combined with Paliperidone. The metabolism of Domperidone can be decreased when combined with Irbesartan. The serum concentration of Domperidone can be increased when it is combined with Palbociclib. The risk or severity of adverse effects can be increased when Pargyline is combined with Domperidone. Thiothixene may increase the QTc-prolonging activities of Domperidone. The serum concentration of Domperidone can be increased when it is combined with Ivacaftor. Sevoflurane may increase the QTc-prolonging activities of Domperidone. The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Domperidone. The serum concentration of Domperidone can be increased when it is combined with Fluconazole. Octreotide may increase the QTc-prolonging activities of Domperidone. The serum concentration of Domperidone can be increased when it is combined with Dihydroergotamine. The metabolism of Domperidone can be increased when combined with Secobarbital. The serum concentration of Domperidone can be increased when it is combined with Mifepristone. The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Domperidone. The serum concentration of Domperidone can be increased when it is combined with Cyclosporine. The risk or severity of adverse effects can be increased when Pheniprazine is combined with Domperidone. Paroxetine may increase the QTc-prolonging activities of Domperidone. The risk or severity of adverse effects can be increased when Furazolidone is combined with Domperidone. Sorafenib may increase the QTc-prolonging activities of Domperidone. The serum concentration of Domperidone can be increased when it is combined with Atazanavir. The serum concentration of Domperidone can be increased when it is combined with Boceprevir. Oxytocin may increase the QTc-prolonging activities of Domperidone. The metabolism of Domperidone can be decreased when combined with Cocaine. The metabolism of Domperidone can be decreased when combined with Duloxetine. The serum concentration of Domperidone can be decreased when it is combined with Peginterferon alfa-2b. The metabolism of Domperidone can be decreased when combined with Terbinafine. The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Domperidone. The risk or severity of adverse effects can be increased when Amphetamine is combined with Domperidone. Flecainide may increase the QTc-prolonging activities of Domperidone. The serum concentration of Domperidone can be increased when it is combined with Olaparib. Rilpivirine may increase the QTc-prolonging activities of Domperidone. The serum concentration of Domperidone can be increased when it is combined with Dronedarone. The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Domperidone. The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Domperidone. Norfloxacin may increase the QTc-prolonging activities of Domperidone. The serum concentration of Domperidone can be decreased when it is combined with Cyproterone acetate. The metabolism of Domperidone can be decreased when combined with Lidocaine. The risk or severity of adverse effects can be increased when Pivhydrazine is combined with Domperidone. The serum concentration of Domperidone can be increased when it is combined with Indinavir. The therapeutic efficacy of Domperidone can be decreased when used in combination with Sarilumab. The serum concentration of Domperidone can be increased when it is combined with Fosamprenavir. Tizanidine may increase the QTc-prolonging activities of Domperidone. Ezogabine may increase the QTc-prolonging activities of Domperidone. The serum concentration of Domperidone can be increased when it is combined with Ceritinib. The serum concentration of Domperidone can be increased when it is combined with Fusidic Acid. The metabolism of Domperidone can be decreased when combined with Mexiletine. The risk or severity of QTc prolongation can be increased when Toremifene is combined with Domperidone. The risk or severity of adverse effects can be increased when Toloxatone is combined with Domperidone. Metronidazole may increase the QTc-prolonging activities of Domperidone. The metabolism of Domperidone can be decreased when combined with Zucapsaicin. The metabolism of Domperidone can be decreased when combined with Tipranavir. The metabolism of Domperidone can be decreased when combined with Betaxolol. The metabolism of Domperidone can be decreased when combined with Darifenacin. The metabolism of Domperidone can be decreased when combined with Clopidogrel. The serum concentration of Domperidone can be increased when it is combined with Lopinavir. The risk or severity of adverse effects can be increased when Safrazine is combined with Domperidone. The serum concentration of Domperidone can be increased when it is combined with Delavirdine. The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Domperidone. The serum concentration of Domperidone can be increased when it is combined with Clarithromycin. The serum concentration of Domperidone can be decreased when it is combined with Siltuximab. The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Domperidone. Doxepin may increase the QTc-prolonging activities of Domperidone. The risk or severity of adverse effects can be increased when Hydracarbazine is combined with Domperidone. Nicardipine may increase the QTc-prolonging activities of Domperidone. Apomorphine may increase the QTc-prolonging activities of Domperidone. Galantamine may increase the QTc-prolonging activities of Domperidone. The metabolism of Domperidone can be decreased when combined with Haloperidol. Promethazine may increase the QTc-prolonging activities of Domperidone. The metabolism of Domperidone can be decreased when combined with Felodipine. Aripiprazole may increase the QTc-prolonging activities of Domperidone. The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Domperidone. The serum concentration of Domperidone can be decreased when it is combined with Mitotane. The metabolism of Domperidone can be decreased when combined with Crisaborole. The serum concentration of Domperidone can be increased when it is combined with Luliconazole. The serum concentration of Domperidone can be increased when it is combined with Netupitant. Lapatinib may increase the QTc-prolonging activities of Domperidone. The metabolism of Domperidone can be increased when combined with Carbamazepine. The serum concentration of Domperidone can be increased when it is combined with Voriconazole. Hydroxyzine may increase the QTc-prolonging activities of Domperidone. The risk or severity of adverse effects can be increased when Iproniazid is combined with Domperidone. The risk or severity of QTc prolongation can be increased when Pimozide is combined with Domperidone. The serum concentration of Domperidone can be increased when it is combined with Simeprevir. The serum concentration of Domperidone can be increased when it is combined with Imatinib. The serum concentration of Domperidone can be increased when it is combined with Nevirapine. Bedaquiline may increase the QTc-prolonging activities of Domperidone. Famotidine may increase the QTc-prolonging activities of Domperidone. The serum concentration of Domperidone can be increased when it is combined with Lumacaftor. The serum concentration of Domperidone can be increased when it is combined with Diltiazem. The metabolism of Domperidone can be decreased when combined with Lumefantrine. Indacaterol may increase the QTc-prolonging activities of Domperidone. Trazodone may increase the QTc-prolonging activities of Domperidone. The serum concentration of Domperidone can be decreased when it is combined with St. John's Wort. Leuprolide may increase the QTc-prolonging activities of Domperidone. Droperidol may increase the QTc-prolonging activities of Domperidone. The metabolism of Domperidone can be decreased when combined with Cholecalciferol. The metabolism of Domperidone can be decreased when combined with Topiroxostat. Vardenafil may increase the QTc-prolonging activities of Domperidone. The metabolism of Domperidone can be decreased when combined with Theophylline. Alfuzosin may increase the QTc-prolonging activities of Domperidone. Domperidone may increase the QTc-prolonging activities of Ivabradine. Risperidone may increase the QTc-prolonging activities of Domperidone. The metabolism of Domperidone can be decreased when combined with Rolapitant. Granisetron may increase the QTc-prolonging activities of Domperidone. The serum concentration of Domperidone can be decreased when it is combined with Teriflunomide. The risk or severity of QTc prolongation can be increased when Sotalol is combined with Domperidone. Propofol may increase the QTc-prolonging activities of Domperidone. The metabolism of Domperidone can be decreased when combined with Rabeprazole.